GLUE · Insider Trading
Monte Rosa Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by GLUE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Matthew Bowen | Principal Accounting Officer | Sell | −13 | −$137 |
| 2026-07-17 | Markus Warmuth | President & CEO | Sell | −9,500 | −$220.22K |
| 2026-07-16 | Jennifer Champoux | Chief Operating Officer | MIXED | — | −$84.41K |
| 2026-07-07 | Sharon Townson | Chief Scientific Officer | MIXED | — | −$103.01K |
| 2026-07-06 | Ali Behbahani | Director | J | −1,000,000 | — |
| 2026-07-01 | Filip Janku | Chief Medical Officer | MIXED | — | −$59.96K |
| 2026-06-25 | Sharon Townson | Chief Scientific Officer | MIXED | — | −$41.58K |
| 2026-06-25 | Jennifer Champoux | Chief Operating Officer | MIXED | — | −$34.84K |
| 2026-06-25 | Filip Janku | Chief Medical Officer | MIXED | −5,845 | −$610.04K |
| 2026-06-18 | Sharon Townson | Chief Scientific Officer | MIXED | — | −$38.58K |
| 2026-06-18 | Jennifer Champoux | Chief Operating Officer | MIXED | — | −$32.68K |
| 2026-06-12 | Anthony M. Manning | Director | A | +25,800 deriv. | — |
| 2026-06-12 | Eric A Hughes | Director | A | +25,800 deriv. | — |
| 2026-06-12 | Jan Skvarka | Director | A | +25,800 deriv. | — |
| 2026-06-12 | Andrew N Schiff | Director | A | +25,800 deriv. | — |
| 2026-06-12 | Kimberly Blackwell | Director | A | +25,800 deriv. | — |
| 2026-06-12 | Christine Siu | Director | A | +25,800 deriv. | — |
| 2026-06-12 | Ali Behbahani | Director | A | +25,800 deriv. | — |
| 2026-06-02 | Markus Warmuth | President & CEO | Sell | −5,466 | −$106.25K |
| 2026-06-01 | Sharon Townson | Chief Scientific Officer | MIXED | — | −$82.38K |
| 2026-05-28 | Jennifer Champoux | Chief Operating Officer | MIXED | — | −$34.84K |
| 2026-05-26 | Jennifer Champoux | Chief Operating Officer | MIXED | — | −$32.68K |
| 2026-05-22 | Anthony M. Manning | Director | MIXED | — | −$138.50K |
| 2026-05-05 | Markus Warmuth | President & CEO | Sell | −5,467 | −$103.45K |
| 2026-04-15 | Markus Warmuth | President & CEO | Sell | −8,000 | −$141.12K |
| 2026-04-10 | Philip Nickson | Chief Business & Legal Officer | Sell | −5,845 | −$103.41K |
| 2026-04-07 | Matthew Bowen | Principal Accounting Officer | A | +4,300 | — |
| 2026-03-05 | Edmund Dunn | Principal Accounting Officer | Sell | −139 | −$2.50K |
| 2026-03-04 | Markus Warmuth | President & CEO | Sell | −5,466 | −$97.97K |
| 2026-03-02 | Edmund Dunn | Principal Accounting Officer | MIXED | — | −$120.25K |
| 2026-02-24 | Filip Janku | Chief Medical Officer | Sell | −9,189 | −$179.16K |
| 2026-01-09 | Markus Warmuth | President & CEO | Sell | −5,466 | −$128.37K |
| 2026-01-05 | Philip Nickson | Chief Business & Legal Officer | MIXED | +24,845 | −$47.86K |
| 2026-01-05 | Jennifer Champoux | Chief Operating Officer | MIXED | +32,371 | −$39.88K |
| 2026-01-05 | Edmund Dunn | Principal Accounting Officer | Sell | −1,039 | −$15.76K |
| 2026-01-05 | Filip Janku | Chief Medical Officer | MIXED | +27,845 | −$47.86K |
| 2026-01-05 | Markus Warmuth | President & CEO | MIXED | +79,865 | −$153.75K |
| 2026-01-05 | Sharon Townson | Chief Scientific Officer | MIXED | +31,845 | −$47.86K |
| 2025-06-16 | Christine Siu | Director | A | +30,700 deriv. | — |
| 2025-06-16 | Anthony M. Manning | Director | A | +30,700 deriv. | — |
| 2025-06-16 | Kimberly Blackwell | Director | A | +30,700 deriv. | — |
| 2025-06-16 | Jan Skvarka | Director | A | +30,700 deriv. | — |
| 2025-06-16 | Ali Behbahani | Director | A | +30,700 deriv. | — |
| 2025-06-16 | Eric A Hughes | Director | A | +30,700 deriv. | — |
| 2025-06-16 | Andrew N Schiff | Director | A | +30,700 deriv. | — |
| 2025-06-04 | Edmund Dunn | Principal Accounting Officer | Sell | −2,062 | −$9.17K |
| 2025-03-25 | Chandra P. Leo | Director | Buy | +10,000 | +$58.38K |
| 2025-01-06 | Markus Warmuth | President & CEO | A | +128,000 | — |
| 2025-01-06 | Jennifer Champoux | Chief Operating Officer | A | +30,000 | — |
| 2025-01-06 | Filip Janku | Chief Medical Officer | A | +36,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Versant Vantage I GP, L.P. | 10%+ Owner | 5,720,827 | $64.19M |
| Markus Warmuth | President & CEO | 585,038 | $6.56M |
| Sharon Townson | Chief Scientific Officer | 67,845 | $761.22K |
| Jennifer Champoux | Chief Operating Officer | 66,722 | $748.62K |
| Filip Janku | Chief Medical Officer | 60,612 | $680.07K |
| Philip Nickson | Chief Business & Legal Officer | 55,000 | $617.10K |
| Matthew Bowen | Principal Accounting Officer | 25,891 | $290.50K |
| Edmund Dunn | Principal Accounting Officer | 22,554 | $253.06K |
| Anthony M. Manning | Director | 10,000 | $112.20K |
| Chandra P. Leo | Director | 10,000 | $112.20K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GLUE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.